Other search tools

About this data

The publication data currently available has been vetted by Vanderbilt faculty, staff, administrators and trainees. The data itself is retrieved directly from NCBI's PubMed and is automatically updated on a weekly basis to ensure accuracy and completeness.

If you have any questions or comments, please contact us.

Results: 1 to 10 of 67

Publication Record

Connections

Age-Related Considerations in Cardio-Oncology.
Screever EM, Meijers WC, Moslehi JJ
(2021) J Cardiovasc Pharmacol Ther 26: 103-113
MeSH Terms: Age Factors, Anthracyclines, Cardiology, Cardiotoxicity, Cardiovascular Diseases, Humans, Medical Oncology, Risk Factors
Added January 23, 2021
0 Communities
1 Members
0 Resources
8 MeSH Terms
Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research.
Johnson DB, Reynolds KL, Sullivan RJ, Balko JM, Patrinely JR, Cappelli LC, Naidoo J, Moslehi JJ
(2020) Lancet Oncol 21: e398-e404
MeSH Terms: Antineoplastic Agents, Immunological, Humans, Medical Oncology, Neoplasms, Patient Care, Patient Education as Topic
Added September 29, 2020
0 Communities
1 Members
0 Resources
MeSH Terms
Vascular medicine and cardio-oncology - A new, evolving clinical frontier.
Versmissen J, Power JR, Moslehi J
(2020) Vasc Med 25: 205-207
MeSH Terms: Antineoplastic Agents, Cancer Survivors, Cardiology, Heart Diseases, Humans, Medical Oncology, Neoplasms, Prognosis, Risk Assessment, Risk Factors, Specialization
Added September 29, 2020
0 Communities
1 Members
0 Resources
MeSH Terms
Reverse Cardio-Oncology: Cancer Development in Patients With Cardiovascular Disease.
Aboumsallem JP, Moslehi J, de Boer RA
(2020) J Am Heart Assoc 9: e013754
MeSH Terms: Cardiology, Cardiovascular Diseases, Humans, Incidence, Inflammation, Inflammation Mediators, Medical Oncology, Neoplasms, Prevalence, Prognosis, Risk Assessment, Risk Factors, Signal Transduction, Specialization, Tumor Hypoxia, Tumor Microenvironment
Added May 29, 2020
0 Communities
1 Members
0 Resources
16 MeSH Terms
Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations.
Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, Herrmann J, Porter C, Lyon AR, Lancellotti P, Patel A, DeCara J, Mitchell J, Harrison E, Moslehi J, Witteles R, Calabro MG, Orecchia R, de Azambuja E, Zamorano JL, Krone R, Iakobishvili Z, Carver J, Armenian S, Ky B, Cardinale D, Cipolla CM, Dent S, Jordan K, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org
(2020) Ann Oncol 31: 171-190
MeSH Terms: Antineoplastic Agents, Consensus, Heart Diseases, Humans, Medical Oncology, Neoplasms
Added May 29, 2020
0 Communities
1 Members
0 Resources
6 MeSH Terms
Mechanisms and clinical course of cardiovascular toxicity of cancer treatment I. Oncology.
Yeh ETH, Ewer MS, Moslehi J, Dlugosz-Danecka M, Banchs J, Chang HM, Minotti G
(2019) Semin Oncol 46: 397-402
MeSH Terms: Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Cardiotoxicity, Cardiovascular Diseases, DNA Topoisomerases, Type II, Humans, Medical Oncology, Molecular Targeted Therapy, Neoplasms, Poly-ADP-Ribose Binding Proteins
Added January 15, 2020
0 Communities
1 Members
0 Resources
10 MeSH Terms
Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology
Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A, Stewart GC, Choueiri TK, Di Carli M, Allenbach Y, Kumbhani DJ, Heinzerling L, Amiri-Kordestani L, Lyon AR, Thavendiranathan P, Padera R, Lichtman A, Liu PP, Johnson DB, Moslehi J
(2019) Circulation 140: 80-91
MeSH Terms: Antineoplastic Agents, Immunological, Cardiology, Clinical Trials as Topic, Humans, Immunotherapy, Medical Oncology, Myocarditis, Neoplasms
Added November 12, 2019
0 Communities
1 Members
0 Resources
8 MeSH Terms
Assessing cardiac safety in oncology drug development.
Seltzer JH, Gintant G, Amiri-Kordestani L, Singer J, Koplowitz LP, Moslehi JJ, Barac A, Yu AF
(2019) Am Heart J 214: 125-133
MeSH Terms: Antineoplastic Agents, Antineoplastic Agents, Immunological, Biomarkers, Cardiologists, Cardiovascular Diseases, Cell Line, Tumor, Clinical Trials as Topic, Data Collection, Drug Development, Drug Screening Assays, Antitumor, Heart, Humans, Immunotherapy, Medical Oncology, Research Design, Trastuzumab
Added November 12, 2019
0 Communities
1 Members
0 Resources
16 MeSH Terms
Translating preclinical MRI methods to clinical oncology.
Hormuth DA, Sorace AG, Virostko J, Abramson RG, Bhujwalla ZM, Enriquez-Navas P, Gillies R, Hazle JD, Mason RP, Quarles CC, Weis JA, Whisenant JG, Xu J, Yankeelov TE
(2019) J Magn Reson Imaging 50: 1377-1392
MeSH Terms: Animals, Brain Neoplasms, Diffusion Magnetic Resonance Imaging, Humans, Hydrogen-Ion Concentration, Hypoxia, Image Processing, Computer-Assisted, Immunotherapy, Macromolecular Substances, Magnetic Resonance Imaging, Medical Oncology, Neoplasm Metastasis, Neoplasm Transplantation, Neoplasms, Oxygen, Reproducibility of Results, Theranostic Nanomedicine, Translational Research, Biomedical
Added March 30, 2020
0 Communities
1 Members
0 Resources
18 MeSH Terms
Cardio-oncology: a novel platform for basic and translational cardiovascular investigation driven by clinical need.
Moslehi J, Fujiwara K, Guzik T
(2019) Cardiovasc Res 115: 819-823
MeSH Terms: Animals, Antineoplastic Agents, Cardiology, Cardiotoxicity, Cardiovascular Diseases, Diffusion of Innovation, Forecasting, Humans, Medical Oncology, Risk Factors, Translational Research, Biomedical
Added November 12, 2019
0 Communities
1 Members
0 Resources
11 MeSH Terms